PotNetwork (POTN) and Miragen Therapeutics (MGEN) Financial Comparison
PotNetwork (OTCMKTS:POTN) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
Earnings and Valuation
This table compares PotNetwork and Miragen Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Miragen Therapeutics||$4.00 million||25.29||-$26.51 million||($1.38)||-2.38|
This is a breakdown of recent recommendations for PotNetwork and Miragen Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Miragen Therapeutics has a consensus target price of $16.36, suggesting a potential upside of 398.69%. Given Miragen Therapeutics’ higher probable upside, analysts plainly believe Miragen Therapeutics is more favorable than PotNetwork.
Volatility & Risk
PotNetwork has a beta of 10.75, suggesting that its share price is 975% more volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.
Institutional and Insider Ownership
0.0% of PotNetwork shares are owned by institutional investors. Comparatively, 36.5% of Miragen Therapeutics shares are owned by institutional investors. 18.9% of Miragen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares PotNetwork and Miragen Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Miragen Therapeutics beats PotNetwork on 5 of the 9 factors compared between the two stocks.
PotNetwork Holdings, Inc, through its subsidiary, First Capital Venture Co., engages in the research, development, and sale of hemp-derived CBD oil products. It also engages in the pre-owned auto dealership business. The company sells its products through distributors and resellers, as well as through its Website. The company was formerly known as SND Auto Group Inc. and changed its name to PotNetwork Holdings, Inc in March 2017. PotNetwork Holdings, Inc is based in Fort Lauderdale, Florida.
About Miragen Therapeutics
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan. The company also develops MRG-107, an inhibitor of miR-155 for treating neuronal amyotrophic lateral sclerosis, and other neurodegenerative indications, including spinal cord injury. It also develops preclinical product candidates for treating various indications, including oncology, visual pathologies, neurodegeneration, and hearing loss. Miragen Therapeutics, Inc. has a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. The company was founded in 2006 and is based in Boulder, Colorado.
Receive News & Ratings for PotNetwork Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PotNetwork and related companies with MarketBeat.com's FREE daily email newsletter.